文献速递颈动脉与弓上血管

CREST-2试验中干预医师资质认证的影响因素

Factors influencing credentialing of interventionists in the CREST-2 trial.
PubMed 文献 · J Vasc Surg · 2019-07-26

CREST-2试验评估无症状重度颈动脉狭窄患者在强化内科管理下血运重建的疗效,其中一支比较强化内科管理联合或不联合颈动脉支架置入术。为确保CAS围手术期低卒中风险,研究对干预医师进行资质认证:基于近24个月连续25例病例数据及自报终身经验例数,必要时要求补充前瞻性注册病例。2014年3月21日至2017年10月14日间,委员会召开102次会议,评估334名干预医师提交的8311例病例;仅9%初次获批,补充培训和新病例后升至46%。

要点

  • CREST-2对CAS干预医师实施严格资质认证,基于近24个月连续25例病例及终身经验例数。
  • 初次评审仅9%获批,补充培训和新病例后升至46%,显示认证门槛较高。
  • 每月CAS手术量是初次评审获批的唯一相关因素,高流量且近期经验多者更易获批。

核心结论

  • CREST-2对干预医师的资质认证需要大量监管和受控系统来评估当前技能水平,并控制专科实践差异、手术经验和围手术期结局。
  • 高流量干预医师,尤其是近期经验更丰富者,更可能获批参与CREST-2。
  • 初次获批不受操作者专科影响。

研究设计与样本

  • CREST-2是一对随机试验,评估无症状重度动脉粥样硬化性狭窄患者在强化内科管理下颈动脉血运重建的相对疗效。
  • 本分析描述CREST-2中CAS干预医师资质认证的方案驱动方法及其结果。
  • 干预医师需经介入管理委员会(IMC)详细审查其近24个月连续25例病例数据及自报终身经验例数。
  • 必要时要求经网络研讨会培训后在配套注册中完成额外前瞻性病例。
  • 审查IMC从2014年3月21日首次正式会议至2017年10月14日的经验。

主要发现

  • IMC共召开102次会议,评估334名干预医师提交的8311例病例。
  • 申请者以心脏病专家或血管外科医生为主,但无单一专科占多数。
  • 中位总经验为130例(IQR 75-266;范围25-2500)。
  • 仅9%(30/334)干预医师在初次评审时获批;提交新病例并附加培训及再评审后,获批率增至46%(153/334)。
  • 获批者的中位自报终身病例经验为211.5例(IQR 100-350),提交评审的中位病例数为30例(IQR 27-35)。

关键数值与推荐

  • 干预医师需基于近24个月连续25例病例数据及自报终身经验例数进行资质认证。
  • 必要时需在网络研讨会培训后在配套注册中完成额外前瞻性病例。
  • 初次评审获批率9%(30/334),补充培训和新病例后升至46%(153/334)。
  • 每月CAS手术量是初次评审获批的唯一相关因素(P < .00001)。
  • 初次获批不受操作者专科影响。

临床怎么用

  • 对于CAS等高风险手术,应基于近期连续病例数据和终身经验例数进行严格资质认证。
  • 仅凭终身经验例数不足以反映当前技能,需结合近期手术量和围手术期结局综合评估。
  • 对未通过初次评审的医师,提供针对性培训和补充病例后再评审可提高获批率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) is a pair of randomized trials assessing the relative efficacy of carotid revascularization in the setting of intensive medical management (IMM) in patients with asymptomatic high-grade atherosclerotic stenosis. One of the trials assesses IMM with or without carotid artery stenting (CAS). Given the low risk of stroke in nonrevascularized patients receiving IMM, it is essential that there be low periprocedural risk of stroke for CAS if it is to show incremental benefit. Thus, credentialing of interventionists to ensure excellence is vital. This analysis describes the protocol-driven approach to credentialing of CAS interventionists for CREST-2 and its outcomes. METHODS: To be eligible to perform stenting in CREST-2, interventionists needed to be credentialed on the basis of a detailed Interventional Management Committee (IMC) review of data from their last 25 consecutive cases during the past 24 months along with self-reported lifetime experience case numbers. When necessary, additional prospective cases performed in a companion registry were requested after webinar training. Here we review the IMC experience from the first formal meeting on March 21, 2014 through October 14, 2017. RESULTS: The IMC had 102 meetings, and 8311 cases submitted by 334 interventionists were evaluated. Most were either cardiologists or vascular surgeons, although no single specialty made up the majority of applicants. The median total experience was 130 cases (interquartile range [IQR], 75-266; range, 25-2500). Only 9% (30/334) of interventionists were approved at initial review; approval increased to 46% (153/334) after submission of new cases with added training and re-review. The median self-reported lifetime case experience for those approved was 211.5 (IQR, 100-350), and the median number of cases submitted for review was 30 (IQR, 27-35). The number of CAS procedures performed per month (case rate) was the only factor associated with approval during the initial cycle of review (P < .00001). CONCLUSIONS: Identification of interventionists who were deemed sufficiently skilled for CREST-2 has required substantial oversight and a controlled system to judge current skill level that controls for specialty-based practice variability, procedural experience, and periprocedural outcomes. High-volume interventionists, particularly those with more recent experience, were more likely to be approved to participate in CREST-2. Primary approval was not affected by operator specialty.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Lal BK, Meschia JF, Roubin GS, et al. Factors influencing credentialing of interventionists in the CREST-2 trial. J Vasc Surg. 2019. PMID: 31353274. doi:10.1016/j.jvs.2019.05.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。